UK-based company Oxford Immunotec Global has unveiled its CE-marked T-SPOT.COVID test to detect a cell-mediated (T cell) immune response to SARS-CoV-2 in human whole blood.

The company has submitted an application to the US Food and Drug Administration (FDA) to obtain emergency use authorisation (EUA) for the ELISPOT-based test.

The T-SPOT.COVID test was shown to identify a SARS-CoV-2 cell-mediated (T cell) immune response in PCR positive individuals with negative serology test results in a clinical study, using specimens collected in the US.

It could complement results obtained by antibody serology to provide a thorough view of a person’s adaptive immune response to Covid-19.

Furthermore, the test can be used in conjunction with serology tests to aid in the clinical assessment of people suspected of Covid-19 but are PCR negative.

Oxford Immunotec CEO Dr Peter Wrighton-Smith said: “Our T-SPOT.COVID test is tailored specifically for the detection and measurement of an individual’s T cell response to SARS-CoV-2 infection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Having the ability to determine an individual’s immune response to SARS-CoV-2 has the potential to support a wide range of needs in our battle against the Covid-19 pandemic.”

The T-SPOT.COVID test has been developed as an evolution of the company’s research use-only T-SPOT Discovery SARS-CoV-2 test, which is used to obtain insights about the immune response to the virus.

In a separate development, the US FDA has granted a EUA to Adaptive Biotechnologies’ T-Detect COVID Test.

The next-generation sequencing (NGS)-based test can detect people with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection by assessing deoxyribonucleic acid sequences from T cells.